---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-055602"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:19:28.586881+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# KalVista changes fiscal year-end from April 30 to December 31

## Summary
- Board approved change effective March 13, 2025; new fiscal year begins January 1, 2026.
- Transition report on Form 10-KT will cover eight-month period May 1 through Dec 31, 2025.
- During transition, a 10-Q for quarter ending July 31, 2025 will be filed, then quarters shift to Sept 30, 2025.

## SEC filing metadata
- accession: 0001193125-25-055602
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312525055602/0001193125-25-055602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312525055602/d938905d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-055602
- JSON: https://secwatch.observer/filing/0001193125-25-055602.json
- Plain text: https://secwatch.observer/filing/0001193125-25-055602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.